Ascendis Pharma A ASND
NASDAQ ASND
$241.94 +3.04 (+1.27%)
As of: Oct 22, 2026 · 2:17 PM EDT

Ascendis Pharma A (ASND) Capital Leases (2012)

Updated

Analysis

Ascendis Pharma A (ASND) Capital Leases (2012) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,169.76 Bn 1,138.35 Bn 19.71 Bn
2 Johnson & Johnson 648.06 Bn 567.92 Bn 17.30 Bn
3 AbbVie 503.37 Bn 476.48 Bn 12.70 Bn
4 Merck 365.39 Bn 319.77 Bn 12.21 Bn
5 Novartis Ag 303.45 Bn 267.44 Bn 11.24 Bn
6 Astrazeneca 269.03 Bn 242.72 Bn 12.86 Bn
7 Amgen 242.08 Bn 197.48 Bn 7.24 Bn
8 Gilead Sciences 194.88 Bn 169.07 Bn 6.22 Bn
9 Pfizer 172.39 Bn 119.04 Bn 10.94 Bn
10 Ascendis Pharma A 14.67 Bn 10.94 Bn 362.22 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 280,426.99
API Access

Ascendis Pharma A Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=ASND&period=max&api_key=YOUR_API_KEY